User login
Dr. Paola A. Gehrig picks presentations she anticipates to be the most interesting at the upcoming Society of Gynecologic Oncology annual meeting in San Diego.
1 – Mutations in homologous recombination genes and response to treatment in GOG 218: An NRG Oncology study
B.S. Norquista, et al.
Study objectives: Gynecologic Oncology Group (GOG) 218 was a phase III, randomized trial of advanced primary ovarian, fallopian tube, and peritoneal carcinoma, examining the role of adding bevacizumab to every-21-day carboplatin and paclitaxel. The objective was to examine whether mutations in homologous recombination genes affect response to treatment.
3 – Efficacy and safety of trabectedin or dacarbazine for the treatment of patients with uterine leiomyosarcoma after prior chemotherapy: A subgroup analysis of the randomized phase III SAR-3007 study
M.L. Hensleya, et al.
Study objectives: In ET743-SAR-3007, the efficacy of trabectedin in patients with advanced leiomyosarcoma (LMS) or liposarcoma (LPS), after chemotherapy failure, was compared with the active comparator dacarbazine. As reported, trabectedin exhibited improved disease control with median progression-free survival of 4.2 months (vs 1.5 months for dacarbazine) (HR 0.55; P less than .0001), with similar efficacy in both LMS and LPS cohorts. An analysis was conducted to assess the efficacy and safety of trabectedin or dacarbazine in the largest subgroup of the study, the 232 women with uterine LMS, who comprised 40.2% of the study participants.
10 – GOG 186H: A randomized phase II evaluation of weekly paclitaxel versus weekly paclitaxel with oncolytic reovirus in the treatment of recurrent or persistent ovarian, fallopian tube, or primary peritoneal cancer
D.E. Cohna, et al.
Study objectives: To assess whether the addition of oncolytic reovirus to weekly paclitaxel treatment prolonged progression-free survival in women with recurrent or persistent ovarian, tubal, or primary peritoneal cancer.
25 – Common single nucleotide polymorphisms associated with ovarian cancer risk contribute to the racial disparity in incidence
A. Berchucka, et al.
Study objectives: Data from the U.S. Surveillance, Epidemiology and End Results (SEER) registry have shown that ovarian cancer incidence is 35% lower in blacks than in whites. Differences in oophorectomy rates and epidemiologic risk factors such as parity and oral contraceptive use explain about 30% of this disparity. The Ovarian Cancer Association Consortium has identified 18 genome-wide significant common low-penetrance single nucleotide polymorphisms (SNPs) that increase ovarian cancer risk. Investigators examined whether these risk alleles are more common in whites than blacks to determine whether this contributes to the racial disparity in ovarian cancer incidence.
47 – A stratified randomized double-blind phase II trial of celecoxib in the treatment of patients with cervical intraepithelial neoplasia: A Gynecologic Oncology Group (GOG 0207) study with translational biomarkers and drug level monitoring
J.S. Radera, et al.
Study objectives: To examine the effect of celecoxib on cervical intraepithelial neoplasia type 3 based on whether or not the patient had regression of disease.
Dr. Gehrig is professor and director of gynecologic oncology at the University of North Carolina at Chapel Hill.
Dr. Paola A. Gehrig picks presentations she anticipates to be the most interesting at the upcoming Society of Gynecologic Oncology annual meeting in San Diego.
1 – Mutations in homologous recombination genes and response to treatment in GOG 218: An NRG Oncology study
B.S. Norquista, et al.
Study objectives: Gynecologic Oncology Group (GOG) 218 was a phase III, randomized trial of advanced primary ovarian, fallopian tube, and peritoneal carcinoma, examining the role of adding bevacizumab to every-21-day carboplatin and paclitaxel. The objective was to examine whether mutations in homologous recombination genes affect response to treatment.
3 – Efficacy and safety of trabectedin or dacarbazine for the treatment of patients with uterine leiomyosarcoma after prior chemotherapy: A subgroup analysis of the randomized phase III SAR-3007 study
M.L. Hensleya, et al.
Study objectives: In ET743-SAR-3007, the efficacy of trabectedin in patients with advanced leiomyosarcoma (LMS) or liposarcoma (LPS), after chemotherapy failure, was compared with the active comparator dacarbazine. As reported, trabectedin exhibited improved disease control with median progression-free survival of 4.2 months (vs 1.5 months for dacarbazine) (HR 0.55; P less than .0001), with similar efficacy in both LMS and LPS cohorts. An analysis was conducted to assess the efficacy and safety of trabectedin or dacarbazine in the largest subgroup of the study, the 232 women with uterine LMS, who comprised 40.2% of the study participants.
10 – GOG 186H: A randomized phase II evaluation of weekly paclitaxel versus weekly paclitaxel with oncolytic reovirus in the treatment of recurrent or persistent ovarian, fallopian tube, or primary peritoneal cancer
D.E. Cohna, et al.
Study objectives: To assess whether the addition of oncolytic reovirus to weekly paclitaxel treatment prolonged progression-free survival in women with recurrent or persistent ovarian, tubal, or primary peritoneal cancer.
25 – Common single nucleotide polymorphisms associated with ovarian cancer risk contribute to the racial disparity in incidence
A. Berchucka, et al.
Study objectives: Data from the U.S. Surveillance, Epidemiology and End Results (SEER) registry have shown that ovarian cancer incidence is 35% lower in blacks than in whites. Differences in oophorectomy rates and epidemiologic risk factors such as parity and oral contraceptive use explain about 30% of this disparity. The Ovarian Cancer Association Consortium has identified 18 genome-wide significant common low-penetrance single nucleotide polymorphisms (SNPs) that increase ovarian cancer risk. Investigators examined whether these risk alleles are more common in whites than blacks to determine whether this contributes to the racial disparity in ovarian cancer incidence.
47 – A stratified randomized double-blind phase II trial of celecoxib in the treatment of patients with cervical intraepithelial neoplasia: A Gynecologic Oncology Group (GOG 0207) study with translational biomarkers and drug level monitoring
J.S. Radera, et al.
Study objectives: To examine the effect of celecoxib on cervical intraepithelial neoplasia type 3 based on whether or not the patient had regression of disease.
Dr. Gehrig is professor and director of gynecologic oncology at the University of North Carolina at Chapel Hill.
Dr. Paola A. Gehrig picks presentations she anticipates to be the most interesting at the upcoming Society of Gynecologic Oncology annual meeting in San Diego.
1 – Mutations in homologous recombination genes and response to treatment in GOG 218: An NRG Oncology study
B.S. Norquista, et al.
Study objectives: Gynecologic Oncology Group (GOG) 218 was a phase III, randomized trial of advanced primary ovarian, fallopian tube, and peritoneal carcinoma, examining the role of adding bevacizumab to every-21-day carboplatin and paclitaxel. The objective was to examine whether mutations in homologous recombination genes affect response to treatment.
3 – Efficacy and safety of trabectedin or dacarbazine for the treatment of patients with uterine leiomyosarcoma after prior chemotherapy: A subgroup analysis of the randomized phase III SAR-3007 study
M.L. Hensleya, et al.
Study objectives: In ET743-SAR-3007, the efficacy of trabectedin in patients with advanced leiomyosarcoma (LMS) or liposarcoma (LPS), after chemotherapy failure, was compared with the active comparator dacarbazine. As reported, trabectedin exhibited improved disease control with median progression-free survival of 4.2 months (vs 1.5 months for dacarbazine) (HR 0.55; P less than .0001), with similar efficacy in both LMS and LPS cohorts. An analysis was conducted to assess the efficacy and safety of trabectedin or dacarbazine in the largest subgroup of the study, the 232 women with uterine LMS, who comprised 40.2% of the study participants.
10 – GOG 186H: A randomized phase II evaluation of weekly paclitaxel versus weekly paclitaxel with oncolytic reovirus in the treatment of recurrent or persistent ovarian, fallopian tube, or primary peritoneal cancer
D.E. Cohna, et al.
Study objectives: To assess whether the addition of oncolytic reovirus to weekly paclitaxel treatment prolonged progression-free survival in women with recurrent or persistent ovarian, tubal, or primary peritoneal cancer.
25 – Common single nucleotide polymorphisms associated with ovarian cancer risk contribute to the racial disparity in incidence
A. Berchucka, et al.
Study objectives: Data from the U.S. Surveillance, Epidemiology and End Results (SEER) registry have shown that ovarian cancer incidence is 35% lower in blacks than in whites. Differences in oophorectomy rates and epidemiologic risk factors such as parity and oral contraceptive use explain about 30% of this disparity. The Ovarian Cancer Association Consortium has identified 18 genome-wide significant common low-penetrance single nucleotide polymorphisms (SNPs) that increase ovarian cancer risk. Investigators examined whether these risk alleles are more common in whites than blacks to determine whether this contributes to the racial disparity in ovarian cancer incidence.
47 – A stratified randomized double-blind phase II trial of celecoxib in the treatment of patients with cervical intraepithelial neoplasia: A Gynecologic Oncology Group (GOG 0207) study with translational biomarkers and drug level monitoring
J.S. Radera, et al.
Study objectives: To examine the effect of celecoxib on cervical intraepithelial neoplasia type 3 based on whether or not the patient had regression of disease.
Dr. Gehrig is professor and director of gynecologic oncology at the University of North Carolina at Chapel Hill.
